Targeted Inactivation of GPR26 Leads to Hyperphagia and Adiposity by Activating AMPK in the Hypothalamus

Lifestyle Change and Mobility in Obese Adults with Type 2 Diabetes

(2012) W. Jack Rejeski et al.   NEW ENGLAND JOURNAL OF MEDICINE

AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice

(2011) Yu Li et al.   Cell Metabolism

GPR26-deficient mice display increased anxiety- and depression-like behaviors accompanied by reduced phosphorylated cyclic AMP responsive element-binding protein level in central amygdala

(2011) L.-L. Zhang et al.   NEUROSCIENCE

Cardiolipin Remodeling by ALCAT1 Links Oxidative Stress and Mitochondrial Dysfunction to Obesity

(2010) Jia Li et al.   Cell Metabolism

Hypothalamic AMP-Activated Protein Kinase Regulates Glucose Production

(2010) C. S. Yang et al.   DIABETES

AMPK-dependent Repression of Hepatic Gluconeogenesis via Disruption of CREB·CRTC2 Complex by Orphan Nuclear Receptor Small Heterodimer Partner

(2010) Ji-Min Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Neuropsychiatric adverse effects signal the end of the line for rimonabant

(2010) Alexandra King   Nature Reviews Cardiology

Obesity and leptin resistance: distinguishing cause from effect

(2010) Martin G. Myers et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome

(2009) Bei B. Zhang et al.   Cell Metabolism

Targeting the CNS to treat type 2 diabetes

(2009) Darleen A. Sandoval et al.   NATURE REVIEWS DRUG DISCOVERY

CB1 antagonists for obesity—what lessons have we learned from rimonabant?

(2009) Vincenzo Di Marzo et al.   Nature Reviews Endocrinology

Role of AMP-Activated Protein Kinase in the Control of Appetite

(2008) B. Kola   JOURNAL OF NEUROENDOCRINOLOGY